148 related articles for article (PubMed ID: 32810723)
1. A population approach of rifampicin pharmacogenetics and pharmacokinetics in Mexican patients with tuberculosis.
Medellin-Garibay SE; Huerta-García AP; Rodríguez-Báez AS; Magaña-Aquino M; Ortiz-Álvarez A; Portales-Pérez DP; Milán-Segovia RDC; Romano-Moreno S
Tuberculosis (Edinb); 2020 Sep; 124():101982. PubMed ID: 32810723
[TBL] [Abstract][Full Text] [Related]
2. Anthropometric and Genetic Factors Associated With the Exposure of Rifampicin and Isoniazid in Mexican Patients With Tuberculosis.
Huerta-García AP; Medellín-Garibay SE; Salazar-González RA; Ortiz-Álvarez A; Magaña-Aquino M; Rodríguez-Pinal CJ; Portales-Pérez DP; Romano-Moreno S; Milán-Segovia RDC
Ther Drug Monit; 2019 Oct; 41(5):648-656. PubMed ID: 30939588
[TBL] [Abstract][Full Text] [Related]
3. Population pharmacokinetics of rifampicin in Mexican patients with tuberculosis.
Milán Segovia RC; Domínguez Ramírez AM; Jung Cook H; Magaña Aquino M; Vigna Pérez M; Brundage RC; Romano Moreno S
J Clin Pharm Ther; 2013 Feb; 38(1):56-61. PubMed ID: 23167603
[TBL] [Abstract][Full Text] [Related]
4. Effects of tuberculosis, race, and human gene SLCO1B1 polymorphisms on rifampin concentrations.
Weiner M; Peloquin C; Burman W; Luo CC; Engle M; Prihoda TJ; Mac Kenzie WR; Bliven-Sizemore E; Johnson JL; Vernon A
Antimicrob Agents Chemother; 2010 Oct; 54(10):4192-200. PubMed ID: 20660695
[TBL] [Abstract][Full Text] [Related]
5. A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine.
Francis J; Zvada SP; Denti P; Hatherill M; Charalambous S; Mungofa S; Dawson R; Dorman S; Gupte N; Wiesner L; Jindani A; Harrison TS; Olagunju A; Egan D; Owen A; McIlleron HM
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30670438
[TBL] [Abstract][Full Text] [Related]
6. Population pharmacokinetics of isoniazid and dose recommendations in Mexican patients with tuberculosis.
Huerta-García AP; Medellín-Garibay SE; Ortiz-Álvarez A; Magaña-Aquino M; Rodríguez-Pinal CJ; Portales-Pérez DP; Romano-Moreno S; Milán-Segovia RDC
Int J Clin Pharm; 2020 Aug; 42(4):1217-1226. PubMed ID: 32638292
[TBL] [Abstract][Full Text] [Related]
7. Effects of genetic variability on rifampicin and isoniazid pharmacokinetics in South African patients with recurrent tuberculosis.
Naidoo A; Chirehwa M; Ramsuran V; McIlleron H; Naidoo K; Yende-Zuma N; Singh R; Ncgapu S; Adamson J; Govender K; Denti P; Padayatchi N
Pharmacogenomics; 2019 Mar; 20(4):225-240. PubMed ID: 30767706
[TBL] [Abstract][Full Text] [Related]
8. SLCO1B1 and SLC10A1 polymorphism and plasma rifampin concentrations in patients with co-morbidity tuberculosis-diabetes mellitus in Baja California, Mexico.
Perea-Jacobo R; Muñiz-Salazar R; Laniado-Laborín R; Zenteno-Cuevas R; Cabello-Pasini A; Ochoa-Terán A; Radilla-Chávez P
Tuberculosis (Edinb); 2022 Sep; 136():102248. PubMed ID: 36055153
[TBL] [Abstract][Full Text] [Related]
9. Bioavailability of two licensed paediatric rifampicin suspensions: implications for quality control programmes.
McIlleron H; Hundt H; Smythe W; Bekker A; Winckler J; van der Laan L; Smith P; Zar HJ; Hesseling AC; Maartens G; Wiesner L; van Rie A
Int J Tuberc Lung Dis; 2016 Jul; 20(7):915-9. PubMed ID: 27287644
[TBL] [Abstract][Full Text] [Related]
10. Variability in plasma rifampicin concentrations and role of
Sileshi T; Makonnen E; Telele NF; Barclay V; Zumla A; Aklillu E
Infect Dis (Lond); 2024 Apr; 56(4):308-319. PubMed ID: 38315168
[TBL] [Abstract][Full Text] [Related]
11. Genetic Determinants of the Pharmacokinetic Variability of Rifampin in Malawian Adults with Pulmonary Tuberculosis.
Sloan DJ; McCallum AD; Schipani A; Egan D; Mwandumba HC; Ward SA; Waterhouse D; Banda G; Allain TJ; Owen A; Khoo SH; Davies GR
Antimicrob Agents Chemother; 2017 Jul; 61(7):. PubMed ID: 28461315
[TBL] [Abstract][Full Text] [Related]
12. Genetic and clinical predictors of rifapentine and isoniazid pharmacokinetics in paediatrics with tuberculosis infection.
Phaisal W; Albitar O; Chariyavilaskul P; Jantarabenjakul W; Wacharachaisurapol N; Ghadzi SMS; Zainal H; Harun SN
J Antimicrob Chemother; 2024 Jun; 79(6):1270-1278. PubMed ID: 38661209
[TBL] [Abstract][Full Text] [Related]
13. SLCO1B1 gene polymorphisms do not influence plasma rifampicin concentrations in a South Indian population.
Ramesh K; Hemanth Kumar AK; Kannan T; Vijayalakshmi R; Sudha V; Manohar Nesakumar S; Bharathiraja T; Lavanya J; Swaminathan S; Ramachandran G
Int J Tuberc Lung Dis; 2016 Sep; 20(9):1231-5. PubMed ID: 27510251
[TBL] [Abstract][Full Text] [Related]
14. Role of pharmacogenetics in rifampicin pharmacokinetics and the potential effect on TB-rifampicin sensitivity among Ugandan patients.
Mukonzo JK; Kengo A; Kutesa B; Nanzigu S; Pohanka A; McHugh TD; Zumla A; Aklillu E
Trans R Soc Trop Med Hyg; 2020 Feb; 114(2):107-114. PubMed ID: 31789383
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics of nevirapine in combination with rifampicin-based short course chemotherapy in HIV- and tuberculosis-infected South African patients.
Elsherbiny D; Cohen K; Jansson B; Smith P; McIlleron H; Simonsson US
Eur J Clin Pharmacol; 2009 Jan; 65(1):71-80. PubMed ID: 18751690
[TBL] [Abstract][Full Text] [Related]
16. Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis.
Abulfathi AA; Decloedt EH; Svensson EM; Diacon AH; Donald P; Reuter H
Clin Pharmacokinet; 2019 Sep; 58(9):1103-1129. PubMed ID: 31049868
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of rifampicin in Mexican patients with tuberculosis and healthy volunteers.
Medellín-Garibay SE; Milán-Segovia Rdel C; Magaña-Aquino M; Portales-Pérez DP; Romano-Moreno S
J Pharm Pharmacol; 2014 Oct; 66(10):1421-8. PubMed ID: 24841364
[TBL] [Abstract][Full Text] [Related]
18. Low rifampicin concentrations in tuberculosis patients with HIV infection.
Gengiah TN; Botha JH; Soowamber D; Naidoo K; Abdool Karim SS
J Infect Dev Ctries; 2014 Aug; 8(8):987-93. PubMed ID: 25116663
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetic model of rifampicin for personalized tuberculosis pharmacotherapy: Effects of SLCO1B1 polymorphisms on drug exposure.
Hoa PQ; Kim HK; Jang TW; Seo H; Oh JY; Kim HC; Shin AY; Min J; Jayanti RP; Hung TM; Anh NK; Ahn S; Long NP; Cho YS; Shin JG;
Int J Antimicrob Agents; 2024 Feb; 63(2):107034. PubMed ID: 37977236
[TBL] [Abstract][Full Text] [Related]
20. Individualised dosing algorithm and personalised treatment of high-dose rifampicin for tuberculosis.
Svensson RJ; Niward K; Davies Forsman L; Bruchfeld J; Paues J; Eliasson E; Schön T; Simonsson USH
Br J Clin Pharmacol; 2019 Oct; 85(10):2341-2350. PubMed ID: 31269277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
